RNC Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

RNC Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,119	Closed	-$216K	–	150
2018 Q3	$216K	Sell	1,119 -105	-9%	-$18.7K	0.01%	131
2018 Q2	$208K	Sell	1,224 -500	-29%	-$77.5K	0.01%	132
2018 Q1	$281K	Sell	1,724 -210	-11%	-$34.3K	0.02%	119
2017 Q4	$290K	Buy	1,934 +191	+11%	+$28.3K	0.02%	119
2017 Q3	$265K	Sell	1,743 -1,235	-41%	-$186K	0.02%	122
2017 Q2	$384K	Buy	2,978 +150	+5%	+$18.1K	0.03%	102
2017 Q1	$309K	Buy	+2,828	New	+$249K	0.02%	110
2015 Q3	–	Sell	-1,919	Closed	-$237K	–	134
2015 Q2	$237K	Sell	1,919 -545	-22%	-$68.7K	0.02%	118
2015 Q1	$291K	Sell	2,464 -392	-14%	-$47K	0.02%	105
2014 Q4	$339K	Buy	2,856 +738	+35%	+$83.1K	0.03%	105
2014 Q3	$238K	Buy	+2,118	New	+$202K	0.02%	108

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

RNC Capital Management's VRTX Position: Q4 2018 in Review

RNC Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2018, closing a stake of 1,119 shares — an estimated $216K sold.

RNC Capital Management first reported a position in VRTX in Q3 2014 and held it in 11 quarters. The position peaked at $384K in Q2 2017. 705 funds tracked by Wall St. Rank hold VRTX as of Q4 2018.

RNC Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
RNC Capital Management sold 1,119 Vertex Pharmaceuticals shares in Q4 2018, an estimated $216K.
RNC Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2014 and held it in 11 quarters.
RNC Capital Management's Vertex Pharmaceuticals position peaked at $384K in Q2 2017.
705 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2018.

Based on RNC Capital Management's 13F filing for Q4 2018, filed 15 Jan 2019.